MRNA - Moderna, Inc.

57.8
7.970   13.789%

Share volume: 22,334,586
Last Updated: 03-04-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.44%

PREVIOUS CLOSE
CHG
CHG%
$49.83
7.97
0.16%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
13%
Profitability 0%
Dept financing 9%
Liquidity 45%
Performance 20%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
9.38%
1 Month
41.42%
3 Months
108.66%
6 Months
129.91%
1 Year
64.16%
2 Year
-39.51%
Key data
Stock price
$57.80
P/E Ratio 
0.00
DAY RANGE
$51.69 - $59.55
EPS 
-$7.26
52 WEEK RANGE
$22.28 - $59.55
52 WEEK CHANGE
$68.51
MARKET CAP 
11.521 B
YIELD 
N/A
SHARES OUTSTANDING 
394.939 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-31-2025
BETA 
0.33
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$10,289,403
AVERAGE 30 VOLUME 
$10,543,813
Company detail
CEO: Stéphane Bancel
Region: US
Website: modernatx.com
Employees: 3,900
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Moderna, Inc. develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. The company has 44 development programs, which includes 26 in clinical trials across seven modalities.

Recent news